Surveyed Gastroenterologists Indicate That Humira Has Advantages Over Remicade in Maintaining Clinical Remission of Crohn's Disease Humira
Will Retain its Status as Decision Resources' Clinical Gold Standard for Crohn's Disease Through 2017, According to a New Report from Decision Resources
WALTHAM, Mass., Jan. 26, /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceuti...
Although Remicade and Humira Are Being Increasingly Prescribed for Crohn's Disease and Ulcerative Colitis, Insurers Are Subjecting Both Drugs to Multiple Cost-Control Strategies
Nearly One-Third of Surveyed Managed Care Organizations Levy Coinsurance
Charges and Other Protocols on Remicade and Humira, According to a New Report from Decision Resources
WALTHAM, Mass., March 4 /PRNewswire/ -- Decision Resources, one of the
world's leading research ...
Decision Resources' Updated Rheumatoid Arthritis Report Now Includes Forecast for Rigel Pharmaceuticals' Fostamatinib Disodium
... tyrosine kinase (Syk) inhibitor fostamatinib disodium will likely precede TNF-alpha inhibitors such as Amgen/Wyeth/Takeda's Enbrel and Abbott/Eisai's humira
in the treatment cascade for rheumatoid arthritis. Phase II data shows that fostamatinib disodium's efficacy is comparable to that of currently-availa...
U.S. Payers Intend to Limit Preferred Coverage to Only One Immune Biologic
...ary Advantages in Immune Biologics: Tightening Payer Control Offers Opportunities for Differentiation , Centocor Ortho Biotech's Remicade and Abbott's humira
stand to most directly benefit from this strategy as these drugs are currently marketed and/or in development for multiple indications.
Certain Arthritis, Crohn's Drugs May Raise Kids' Cancer Risk: FDA
...errupting a protein that causes inflammation and damage to bones, cartilage and other tissue. They include Remicade (infliximab), Enbrel (etanercept), humira
(adalimumab), Cimzia (certolizumab pegol) and Simponi (golimumab).
"FDA announced that it has completed its analysis of TNF blockers and has concl...
Brazil's Rheumatoid Arthritis Drug Market Will Grow $115 Million by 2013
...eaders were the tumor necrosis factor-alpha (TNF-alpha) inhibitors Abbott's humira
and Schering-Plough's Remicade which recorded sales of $50 million and $43 ...in Rio de Janeiro, rheumatologists from Sao Paulo and Belo Horizonte prefer humira
and Remicade, respectively.
"Competition among TNF-alpha inhibito...
Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit
...trol Offers Opportunities for Differentiation , the majority of surveyed pharmacy directors say they currently cover Amgen/Wyeth's Enbrel and Abbott's humira
solely as a pharmacy benefit, but cover other immune biologics as a medical benefit.
The report finds that payers expect the shift of biolog...
Abbott Reports Strong Second Quarter Results; Confirms Double-Digit Earnings Growth Outlook for 2009
...orable 12.4 percent effect of exchange rates. U.S. humira
sales were $635 million, up 20.9 percent.
$635 20.9 $676 44.0 (2...ange Reported
$1,311 32.8 (12....
Global Autoimmune Disease Therapeutics Market to Reach $50 Billion by 2015, According to a New Report by Global Industry Analysts
...e world's largest drug market, the US, is due primarily to the inclusion of humira
and Enbrel into Medicare Part D reimbursement in early 2006. New products t...ay treatment of autoimmune diseases include TNF inhibitors, such as Enbrel, humira
and Remicade. New products in the market, such as Rituxan and Orencia made ...
Once Monthly Dosing: How Much of a Competitive Advantage is it? Rheumatologists Provide Insight in the Baseline Report of LaunchTrends(TM): SIMPONI(TM)
...he majority of RA patients likely to be placed on SIMPONI are expected to be switched from current biologic agents, primarily impacting use of Enbrel, humira
and Remicade. The main advantages that clinicians perceive for SIMPONI compared to currently available agents are the monthly dosing regimen and self ...
Humira in Medical Technology
Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work
Productivity in Patients with Rheumatoid Arthritis
One Groundbreaking Study Showed 11 Percent Fewer RA Patients
Reported Job Loss When Treated With HUMIRA
Compared to Methotrexate Alone
BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ --
Rheumatoid arthritis (RA) is one of the most common causes of
disability in the Weste...
Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
... Additional Analysis Shows humira
Effectively Treats Adult Patients with Moderate t...ks, patients who had
achieved adequate response to humira
(as measured by PASI 75, or greater
than 75 percen...ed into two groups. One group
continued to receive humira
and the other was given placebo. Beginning at
Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
... Three of Four humira
Patients from CHARM Study in Remission at One Year...study author. "In this study, many
patients taking humira
during a lengthened treatment period showed clinic...ongoing extension study focused on the
efficacy of humira
in maintaining remission and achieving response du...
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
... Fifth Disease Indication for humira
Provides Patients with Visible
Clearance of Infl...systemic therapies are medically less
should only be administered to patients who will b... or better
at week 16 of treatment versus placebo. humira
has 10 years of clinical
trial experience beginnin...
Abbott's m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
...he m2000 and HIV-1 viral load test,
PathVysion and humira
are just a few examples of the caliber of research...iated with congenital disorders and cancer. About humira
In the United States, humira
is approved by the Food and Drug
New Analysis of Data Shows Treatment With Abbott's Humira
(Adalimumab) Significantly Reduced Disease-Related Hospitalization
for Patients with Crohn's Disease
Data Showed 57 Percent Reduction in Risk of Hospit...ted to assess the effect of ongoing treatment with humira
the risk of hospitalization. At one year, this ...ent) were more than twice as
likely as patients on humira
(5.9 percent; p<0.01) to be
hospitalized from Croh...
Halozyme Therapeutics' Enhanze Technology Large Protein Molecule
Therapeutic Clinical Trial Results Presented at the 34th Annual
Meeting of the Controlled Release Society
... - Co-Injection of rHuPH20 with humira
Estimated to Increase the
Maximal Steady State Sub...ging from
1,600 U to 12,800 U) and a fixed dose of humira
(40 mg) injected
every two weeks. Patients with rh...ctions were compared with
regard to PK and safety. humira
is a registered trademark of Abbott
Humira in Biological News
Researchers create mouse lacking key inflammation gene
...own and studied NF-kB transcriptional regulator.
Drugs regulating TNF-alpha through the better-known NF-kB pathway such as Remicade, Embrel, and humira
represent a multibillion market. The LITAF transcription factor offers a new approach to treating inflammatory disorders along with other immunologic...
Humira in Biological Technology
Raptiva Withdrawal Offers Upside for Enbrel and Humira According to Latest BioTrends Survey of U.S. Dermatologists
EXTON, Pa., May 28 /PRNewswire/ -- BioTrends Research Group today released its syndicated report TreatmentTrends (R) : Psoriasis , the fourth annual survey of U.S. Dermatologists (n=150). The report, based on results of an on-line survey fielded in April, highlights shifting trends in th...
Abbott Annual Meeting Highlights Outstanding 2007 Results, International Growth and Near-Term Pipeline
...dministration (FDA) approval in the first quarter. Abbott also received approval from the Japanese Ministry of Health, Labour and Welfare for humira
for the treatment of rheumatoid arthritis in patients with inadequate response to conventional therapy. -- SIMCOR(R), a fixed-dose combinatio...
Centocor/Janssen-Cilag's Ustekinumab Will Become the Gold Standard for Psoriasis By 2011
...b has advantages over
sales-leading Enbrel on this attribute.
"Clinical data and thought leader opinion indicate that ustekinumab and
outperform Enbrel on efficacy and delivery measures,"
said Irene Koulinska, analyst at Decision Resources. "But the major
improvement in efficacy offe...
Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
almost 20 percent achieving complete clearance, humira
promise for physicians and people... decision granting the marketing authorization for humira
treatment for psoriasis in the European Union...s
indication. "The skin clearance we have seen in humira
psoriasis clinical trials,
combined with ten years...
First half of 2006 roundup: Big Pharma trumps biotech
...n to acquire new products that will generate in excess of $1 billion each.
The case of Abbott Labs' stock price is a little strange as its new drug humira
continues to grow beyond original expectations and has achieved additional FDA labeling approval. Furthermore, Abbott's move to aid Boston Scientific ...